^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PCM1-JAK2 fusion

    i
    Other names: PCM1, Pericentriolar Material 1, Pericentriolar Material 1 Protein, HPCM-1, Pericentriolar Material 1, PCM1, PTC4, JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
    Entrez ID:
    3717; 5108
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    over2years
    PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature. (PubMed, Oncologist)
    This rare condition may be increasingly detected with wider use of genomics. Ruxolitinib can yield hematologic and molecular remissions. However, HSCT is, at this time, the only potentially curative treatment. Useful prognostic markers are needed to determine appropriate timing for HSCT in patients with MPN. Patients presenting with acute leukemia have a poor prognosis.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • PCM1 (Pericentriolar Material 1)
    |
    PCM1-JAK2 fusion • JAK2 fusion • PCM1-JAK2 fusion
    |
    Jakafi (ruxolitinib)
    over2years
    Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion. (PubMed, JCO Precis Oncol)
    No abstract available
    Clinical • Journal
    |
    JAK2 (Janus kinase 2) • PCM1 (Pericentriolar Material 1)
    |
    PCM1-JAK2 fusion • JAK2 fusion • PCM1-JAK2 fusion
    over3years
    JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. (PubMed, Am J Surg Pathol)
    These findings suggest that a subset of CD30+ ALK- systemic PTCL with anaplastic morphology carry JAK2 rearrangements, some of which appear to show CHL-like morphologic features. The presence of JAK2 rearrangements in cases of CD30+ PTCL augments current classification and may provide a therapeutic target via JAK2 inhibition.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PCM1 (Pericentriolar Material 1) • FUT4 (Fucosyltransferase 4)
    |
    ALK fusion • TNFRSF8 expression • ALK negative • PCM1-JAK2 fusion • JAK2 fusion • JAK2 rearrangement • PCM1-JAK2 fusion
    over3years
    Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis. (PubMed, Curr Hematol Malig Rep)
    Many conditions, both benign and malignant, can be associated with an increase in mature circulating monocytes. After reasonably excluding a secondary or reactive monocytosis, there should be a concern for and investigation of malignant monocytosis, which includes hematopathologic review of blood and marrow tissues, flow cytometric analysis, and cytogenetic and molecular studies to arrive at an appropriate diagnosis.
    Clinical • Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • PCM1 (Pericentriolar Material 1)
    |
    ASXL1 mutation • TET2 mutation • SRSF2 mutation • FGFR1 fusion • PCM1-JAK2 fusion • JAK2 fusion • PCM1-JAK2 fusion